SOUTH SAN FRANCISCO, Calif. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2021 financial results on Monday,
Latest Imaging Mass Cytometry Discoveries in Infectious Disease, Immuno-Oncology and the Tumor Microenvironment from Expert Users of the Technology SOUTH SAN FRANCISCO, Calif. , Oct. 18, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a
Native Reading of Hyperion Imaging System Data Files on the Visiopharm Platform to Streamline Data Analysis for Researchers SOUTH SAN FRANCISCO, Calif. , Oct. 12, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life
Department of Women’s and Children’s Health to Work with Fluidigm on CyTOF Research Applications, Product Development SOUTH SAN FRANCISCO, Calif. , Sept. 28, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
SOUTH SAN FRANCISCO, Calif. , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite , President and CEO, and Vikram Jog, Chief
Findings in Nature Communications Provide Insights That May Help Guide Patient Care Research Study Conducted in Collaboration with Fluidigm’s Therapeutic Insights Services SOUTH SAN FRANCISCO, Calif. , Aug. 31, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology
SOUTH SAN FRANCISCO, Calif. , Aug. 09, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that company management will participate in the following investor
Base business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million . SOUTH SAN FRANCISCO, Calif. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools
Collaboration Focusing on Advancing CRO Capabilities in Drug Development Utilizing the Hyperion Imaging System SOUTH SAN FRANCISCO, Calif. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
Objective of Agreement is Comprehensive Portfolio for Biomarker Discovery and Drug Development SOUTH SAN FRANCISCO, Calif. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health
